325 related articles for article (PubMed ID: 27200300)
1. Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience.
Mercado C; Kress MA; Cyr RA; Chen LN; Yung TM; Bullock EG; Lei S; Collins BT; Satinsky AN; Harter KW; Suy S; Dritschilo A; Lynch JH; Collins SP
Front Oncol; 2016; 6():114. PubMed ID: 27200300
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
[TBL] [Abstract][Full Text] [Related]
3. Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes.
Carrasquilla M; Sholklapper T; Pepin AN; Hodgins N; Lei S; Rashid A; Danner M; Zwart A; Bolanos G; Ayoob M; Yung T; Aghdam N; Collins B; Suy S; Kumar D; Hankins R; Kowalczyk K; Dawson N; Collins S
Front Oncol; 2023; 13():1240939. PubMed ID: 38074646
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.
Bhattasali O; Chen LN; Woo J; Park JW; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2014 Feb; 9():52. PubMed ID: 24512837
[TBL] [Abstract][Full Text] [Related]
6. Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction.
Repka MC; Guleria S; Cyr RA; Yung TM; Koneru H; Chen LN; Lei S; Collins BT; Krishnan P; Suy S; Dritschilo A; Lynch J; Collins SP
Front Oncol; 2016; 6():122. PubMed ID: 27242962
[TBL] [Abstract][Full Text] [Related]
7. Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.
Paydar I; Pepin A; Cyr RA; King J; Yung TM; Bullock EG; Lei S; Satinsky A; Harter KW; Suy S; Dritschilo A; Lynch JH; Kole TP; Collins SP
Front Oncol; 2017; 7():5. PubMed ID: 28224113
[TBL] [Abstract][Full Text] [Related]
8. Potency preservation following stereotactic body radiation therapy for prostate cancer.
Obayomi-Davies O; Chen LN; Bhagat A; Wright HC; Uhm S; Kim JS; Yung TM; Lei S; Batipps GP; Pahira J; McGeagh KG; Collins BT; Kowalczyk K; Bandi G; Kumar D; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Nov; 8():256. PubMed ID: 24180317
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
[TBL] [Abstract][Full Text] [Related]
10. Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP).
Pepin A; Aghdam N; Shah S; Kataria S; Tsou H; Datta S; Danner M; Ayoob M; Yung T; Lei S; Gurka M; Collins BT; Krishnan P; Suy S; Hankins R; Lynch JH; Collins SP
Front Oncol; 2020; 10():555. PubMed ID: 32432033
[No Abstract] [Full Text] [Related]
11. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806).
Isfahanian N; Lukka H; Dayes I; Quan K; Schnarr KL; Douvi G; Goldberg M; Wright J; Swaminath A; Chow T; Diamond K; Cutz JC; Kavsak P; Thabane L; Tsakiridis T
Clin Genitourin Cancer; 2020 Aug; 18(4):e410-e415. PubMed ID: 32265129
[TBL] [Abstract][Full Text] [Related]
12. Proctitis following stereotactic body radiation therapy for prostate cancer.
Joh DY; Chen LN; Porter G; Bhagat A; Sood S; Kim JS; Moures R; Yung T; Lei S; Collins BT; Ju AW; Suy S; Carroll J; Lynch JH; Dritschilo A; Collins SP
Radiat Oncol; 2014 Dec; 9():277. PubMed ID: 25497602
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?
Woo JA; Chen LN; Wang H; Cyr RA; Bhattasali O; Kim JS; Moures R; Yung TM; Lei S; Collins BT; Suy S; Dritschilo A; Lynch JH; Collins SP
Front Oncol; 2015; 5():77. PubMed ID: 25874188
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15).
Aghdam N; Pepin A; Buchberger D; Hirshberg J; Lei S; Ayoob M; Danner M; Yung T; Kumar D; Collins BT; Lynch J; Kataria S; Suy S; Collins SP
Front Oncol; 2020; 10():1060. PubMed ID: 32719744
[No Abstract] [Full Text] [Related]
15. The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer.
Koneru H; Cyr R; Feng LR; Bae E; Danner MT; Ayoob M; Yung TM; Lei S; Collins BT; Saligan L; Simeng S; Kumar D; Collins SP
Cureus; 2016 Jul; 8(7):e669. PubMed ID: 27551649
[TBL] [Abstract][Full Text] [Related]
16. Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer.
Pepin A; Pernia M; Danner MT; Ayoob M; Yung TM; Lei S; Collins BT; Simeng S; Aghdam N; Collins SP
Cureus; 2021 Mar; 13(3):e13780. PubMed ID: 33842156
[TBL] [Abstract][Full Text] [Related]
17. Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.
Vargas CE; Alam NB; Terk M; Niska JR; Cesaretti J; Swartz D; Vashi A; Kasraeian A; West CS; Blasser M; Moore C
Cancer Treat Res Commun; 2019; 19():100119. PubMed ID: 30772671
[TBL] [Abstract][Full Text] [Related]
18. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial.
Yasar B; Suh YE; Chapman E; Nicholls L; Henderson D; Jones C; Morrison K; Wells E; Henderson J; Meehan C; Sohaib A; Taylor H; Tree A; van As N
Int J Radiat Oncol Biol Phys; 2024 Mar; ():. PubMed ID: 38499253
[TBL] [Abstract][Full Text] [Related]
20. Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design.
Paydar I; Cyr RA; Yung TM; Lei S; Collins BT; Chen LN; Suy S; Dritschilo A; Lynch JH; Collins SP
Front Oncol; 2016; 6():167. PubMed ID: 27489794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
